These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8262690)

  • 21. The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans.
    Lammers JW; Minette P; McCusker M; Barnes PJ
    Am Rev Respir Dis; 1989 Feb; 139(2):446-9. PubMed ID: 2521552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm.
    Sposato B; Mariotta S; Ricci A; Bruno P; Terzano C; Mannino F
    Eur Rev Med Pharmacol Sci; 2005; 9(2):117-23. PubMed ID: 15945501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction.
    Raissy HH; Harkins M; Esparham A; Kelly HW
    Pharmacotherapy; 2007 Sep; 27(9):1231-6. PubMed ID: 17723076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of salbutamol and ipratropium bromide on arterial blood gases in patients with stable COPD].
    Ozdemir T; Geçkin E; Oğüş C; Cilli A
    Tuberk Toraks; 2003; 51(2):132-7. PubMed ID: 15143418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A trial of ipratropium bromide dose optimalization in patients with atopic asthma].
    Karwat K
    Pneumonol Alergol Pol; 1995; 63(9-10):539-43. PubMed ID: 8620176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of ipratropium bromide inhalation in stable asthma.
    Ailani RK; Shah SP; Koyande D; Kudalkar SS; Kodge K; Deshmukh YA
    J Assoc Physicians India; 1995 Jan; 43(1):36, 41. PubMed ID: 9282638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease.
    Dunst MN
    Am Rev Respir Dis; 1989 Oct; 140(4):1174. PubMed ID: 2529802
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison between long-term treatment of chronic bronchitic airway obstruction with ipratropium bromide and metaproterenol.
    Ashutosh K; Lang H
    Ann Allergy; 1984 Nov; 53(5):401-6. PubMed ID: 6238558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Response to inhaled bronchodilators in chronic airway obstruction].
    Holten K
    Tidsskr Nor Laegeforen; 1993 Feb; 113(4):444-7. PubMed ID: 8465284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Response of airflow to the administration of bronchodilator agents in patients with chronic obstructive lung disease or asthma].
    Barbas CS; Barbas Filho JV; do Amaral e Silva E; Stávale ML; Amato Mde P
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(4):163-5. PubMed ID: 1843712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma.
    Brandao DC; Lima VM; Filho VG; Silva TS; Campos TF; Dean E; de Andrade AD
    J Asthma; 2009 May; 46(4):356-61. PubMed ID: 19484669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group.
    Chest; 1997 Dec; 112(6):1514-21. PubMed ID: 9404747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of pirenzepine, a selective M1 muscarinic receptor antagonist, on the bronchial tree patency in patients with bronchial asthma].
    Siergiejko Z; Rutkowski R; Chyrek-Borowska S
    Pneumonol Alergol Pol; 1991; 59(3-4):96-101. PubMed ID: 1843915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of terfenadine and ipratropium bromide on ultrasonically nebulized distilled water-induced asthma.
    Azevedo M; da Costa JT; Fontes P; da Silva JP; Araujo O
    J Int Med Res; 1990; 18(1):37-49. PubMed ID: 2139858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease.
    On LS; Boonyongsunchai P; Webb S; Davies L; Calverley PM; Costello RW
    Am J Respir Crit Care Med; 2001 May; 163(6):1320-5. PubMed ID: 11371395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of spirometry on the management of chronic obstructive airway disease.
    Spann SJ
    J Fam Pract; 1983 Feb; 16(2):271-5. PubMed ID: 6822797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients.
    Ukena D; Wehinger C; Engelstätter R; Steinijans V; Sybrecht GW
    Eur Respir J; 1993 Mar; 6(3):378-82. PubMed ID: 8472828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of ipratropium bromide on lung function in patients with cystic fibrosis].
    Wiebicke W; Poynter A; Montgomery M; Pagtakhan R
    Pneumologie; 1990 Feb; 44 Suppl 1():277-8. PubMed ID: 2142293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bronchoconstriction by nebulized metabisulfite solutions (SO2) and its modification by ipratropium bromide.
    Seale JP; Temple DM; Tennant CM
    Ann Allergy; 1988 Sep; 61(3):209-13. PubMed ID: 2970816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose of nebulized ipratropium bromide in acute severe asthma.
    Whyte KF; Gould GA; Jeffrey AA; Airlie MA; Flenley DC; Douglas NJ
    Respir Med; 1991 Nov; 85(6):517-20. PubMed ID: 1837931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.